Reduction in tamoxifen-induced CYP3A2 expression and DNA adducts using antisense technology

Molecular Carcinogenesis

Volumn 45, Issue 2, 2006, Pages 118-125

  Mahadevan, Brinda ^a   Arora, Vikram ^b   Schild, Laura J ^c   Keshava, Channa ^d   Cate, Melissa L ^b   Iversen, Patrick L ^b   Poirier, Miriam C ^c   Weston, Ainsley ^d   Pereira, Clifford ^a   Baird, William M ^a  

^a OREGON STATE UNIVERSITY   (United States)

^b AVI BioPharma   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

Antisense; CYP3A2; Cytochrome P450; DNA adducts; Microarray

Indexed keywords

AVI 4472; AVI 4557; COMPLEMENTARY DNA; CYTOCHROME P450 3A2; NUCLEOTIDE; OLIGOMER; TAMOXIFEN CITRATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA ADDUCT; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE INDUCTION; GENETIC TRANSCRIPTION; GENOTOXICITY; IMMUNOBLOTTING; LIVER; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN; RNA TRANSLATION; TOXICITY TESTING;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTISENSE ELEMENTS (GENETICS); ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2B1; DNA ADDUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; LIVER; MALE; MEMBRANE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; TAMOXIFEN; TOXICITY TESTS;

ANIMALIA;

EID: 32044443871     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20143     Document Type: Article

References (46)

1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
2. Poirier MC, Schild LJ. The genotoxicity of tamoxifen: Extent and consequences, Kona, Hawaii, January 23, 2003. Mutagenesis 2003;18:395-399.
3. Curtis RE, Freedman DM, Sherman ME, Fraumeni JF Jr. Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst 2004;96:70-74.
4. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 1993;53:3919-3924.
5. Carthew P, Rich KJ, Martin EA, et al. DNA damage as assessed by 32P-postlabelling in three rat strains exposed to dietary tamoxifen: The relationship between cell proliferation and liver tumour formation. Carcinogenesis 1995;16: 1299-1304.
6. Brown K. Breast cancer chemoprevention: Risk-benefit effects of the antioestrogen tamoxifen. Expert Opin Drug Saf 2002;1:253-267.
7. Phillips DH. Understanding the genotoxicity of tamoxifen? Carcinogenesis 2001;22:839-849.
8. Phillips DH, Carmichael PL, Hewer A, Cole KJ, Poon GK. alpha-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res 1994;54:5518-5522.
9. Potter GA, McCague R, Jarman M. A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis 1994;15:439-442.
10. Poon GK, Walter B, Lonning PE, Norton MN, McCague R. Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer. Drug Metab Dispos 1995;23:377-382.
11. Shibutani S, Shaw PM, Suzuki N, Dasaradhi L, Duffel MW, Terashima I. Sulfation of alpha-hydroxytamoxifen catalyzed by human hydroxysteroid sulfotransferase results in tamoxifen-DNA adducts. Carcinogenesis 1998;19:2007-2011.
12. Osborne MR, Hewer A, Hardcastle IR, Carmichael PL, Phillips DH. Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res 1996;56:66-71.
13. Dasaradhi L, Shibutani S. Identification of tamoxifen-DNA adducts formed by alpha-sulfate tamoxifen and alpha-acetoxytamoxifen. Chem Res Toxicol 1997;10:189-196.
14. Kim SY, Suzuki N, Santosh Laxmi YR, Rieger R, Shibutani S. Alpha-hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes. Chem Res Toxicol 2003;16:1138-1144.
15. Notley LM, De Wolf CJ, Wunsch RM, Lancaster RG, Gillam EM. Bioactivation of tamoxifen by recombinant human cytochrome p450 enzymes. Chem Res Toxicol 2002;15: 614-622.
16. Boocock DJ, Brown K, Gibbs AH, Sanchez E, Turteltaub KW, White IN. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 2002;23:1897-1901.
17. Arora V, Iversen PL. Redirection of drug metabolism using antisense technology. Curr Opin Mol Ther 2001;3:249-257.
18. Arora V, Hannah TL, Iversen PL, Brand RM. Transdermal use of phosphorodiamidate morpholino oligomer AVI-4472 inhibits cytochrome P450 3A2 activity in male rats. Pharm Res 2002;19:1465-1470.
19. Arora V, Cate ML, Ghosh C, Iversen PL. Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism. Drug Metab Dispos 2002;30:757-762.
20. Arora V, Knapp DC, Reddy MT, Weller DD, Iversen PL. Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats. J Pharm Sci 2002;91: 1009-1018.
21. Summerton J, Weller D. Morpholino antisense oligomers: Design, preparation, and properties. Antisense Nucleic Acid Drug Dev 1997;7:187-195.
22. Iversen PL. Phosphorodiamidate Morpholino oligomers. In: 'Antisense drug technology - principles, strategies and applications'. 2001. pp 375-389.
23. Iversen PL, Arora V, Acker AJ, Mason DH, Devi GR. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin Cancer Res 2003;9:2510-2519.
24. Hudziak RM, Barofsky E, Barofsky DF, Weller DL, Huang SB, Weller DD. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev 1996;6:267-272.
25. Summerton J. Morpholino antisense oligomers: The case for an RNase H-independent structural type. Biochim Biophys Acta 1999;1489:141-158.
26. Giles RV, Spiller DG, Clark RE, Tidd DM. Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNA. Antisense Nucleic Acid Drug Dev 1999;9: 213-220.
27. Phillips DH, Hewer A, White IN, Farmer PB. Co-chromatography of a tamoxifen epoxide-deoxyguanylic acid adduct with a major DNA adduct formed in the livers of tamoxifen-treated rats. Carcinogenesis 1994;15:793-795.
28. White IN, de Matteis F, Davies A, et al. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2, and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 1992;13:2197-2203.
29. Divi RL, Dragan YP, Pitot HC, Poirier MC. Immunohistochemical localization and semi-quantitation of hepatic tamoxifen-DNA adducts in rats exposed orally to tamoxifen. Carcinogenesis 2001;22:1693-1699.
30. Carthew P, Lee PN, Edwards RE, Heydon RT, Nolan BM, Martin EA. Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat. Arch Toxicol 2001;75: 375-380.
31. Kedar RP, Bourne TH, Powles TJ, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994;343: 1318-1321.
32. van Leeuwen FE, Benraadt J, Coebergh JW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-452.
33. Umemoto A, Monden Y, Komaki K, et al. Tamoxifen-DNA adducts formed by alpha-acetoxytamoxifen N-oxide. Chem Res Toxicol 1999;12:1083-1089.
34. Shibutani S, Ravindernath A, Suzuki N, et al. Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 2000;21:1461-1467.
35. Shibutani S, Suzuki N, Laxmi YR, et al. Identification of tamoxifen-DNA adducts in monkeys treated with tamoxifen. Cancer Res 2003;63:4402-4406.
36. Desjardins JP, Iversen PL. Inhibition of the rat cytochrome P450 3A2 by an antisense phosphorothioate oligodeoxynucleotide in vivo. J Pharmacol Exp Ther 1995;275:1608-1613.
37. Divi RL, XX MRO, Hewer A, Phillipsand DH, Poirier MC. Tamoxifen-DNA adduct formation in rat liver determined by immunoassay and 33P postlabeling. Cancer Res 1999; 59:4829-4833.
38. Schild LJ, Divi RL, Beland FA, et al. Formation of tamoxifen-DNA adducts in multiple organs of adult female cynomolgus monkeys dosed with tamoxifen for 30 days. Cancer Res 2003;63:5999-6003.
39. Kasahara T, Hashiba M, Harada T, Degawa M. Change in the gene expression of hepatic tamoxifen-metabolizing enzymes during the process of tamoxifen-induced hepatocarcinogenesis in female rats. Carcinogenesis 2002;23: 491-498.
40. Gerhold D, Lu M, Xu J, Austin C, Caskey CT, Rushmore T. Monitoring expression of genes involved in drug metabolism and toxicology using DNA microarrays. Physiol Genomics 2001;5:161-170.
41. Marton MJ, DeRisi JL, Bennett HA, et al. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat Med 1998;4:1293-1301.
42. Lockhart DJ, Dong H, Byrne MC, et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996;14:1675-1680.
43. Davis W, Hewer A, Rajkowski KM, Meinl W, Glatt H, Phillips DH. Sex differences in the activation of tamoxifen to DNA binding species in rat liver in vivo and in rat hepatocytes in vitro: Role of sulfotransferase induction. Cancer Res 2000;60:2887-2891.
44. Kawai M, Bandiera SM, Chang TK, Poulet FM, Vancutsem PM, Bellward GD. Modulation of hepatic CYP2A1, CYP2C11, and CYP3A9 expression in adult rats by neonatal administration of tamoxifen. Drug Metab Dispos 1999; 27:1392-1398.
45. Robertson GR, Farrell GC, Liddle C. Sexually dimorphic expression of rat CYP3A9 and CYP3A18 genes is regulated by growth hormone. Biochem Biophys Res Commun 1998; 242:57-60.
46. Kupfer D, Mani C, Lee CA, Rifkind AB. Induction of tamoxifen-4- hydroxylation by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), beta-naphthoflavone (beta NF), and phenobarbital (PB) in avian liver: Identification of P450 TCDDAA as catalyst of 4-hydroxylation induced by TCDD and beta NF. Cancer Res 1994;54:3140-3144.